PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1840.05%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 3.35%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
1.35%
D&A growth under 50% of Drug Manufacturers - Specialty & Generic median of 0.17%, or significantly exceeding it. Jim Chanos would suspect overcapacity or misallocated capex if new assets do not pay off quickly.
-20.81%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-12.00%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-164.27%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 4.45%. Seth Klarman would see an advantage if sales remain robust.
16.45%
AR growth of 16.45% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.
-419.33%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
-88.44%
AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
-191.93%
Other WC usage shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
8421.81%
Growth of 8421.81% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
-163.79%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is 12.74%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
81.11%
CapEx growth of 81.11% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
84.61%
Acquisition growth of 84.61% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or partial deals fueling that difference.
99.61%
Purchases growth of 99.61% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or new strategic positions driving the difference.
No Data
No Data available this quarter, please select a different quarter.
-97.85%
We reduce “other investing” yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
98.31%
Investing flow of 98.31% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
90.30%
Debt repayment growth of 90.30% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
117.55%
Issuance growth of 117.55% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
-117.55%
We reduce yoy buybacks while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a potential missed chance unless expansions promise higher returns.